U.S. Stocks Move | Trex Bio (TRXB.US) Debuts on the U.S. Stock Market, Drops Over 1.3% After Opening

According to Zhihui Finance APP, on Friday, Trex Bio (TRXB.US) debuted on the US stock market. As of press time, the stock had fallen by more than 1.3%, trading at $13.805. The IPO price was $14. TRex Bio is a clinical-stage biopharmaceutical company dedicated to developing drugs that enhance the function of regulatory T cells (Treg) in inflamed human tissues, with the goal of restoring immune balance and repairing barrier damage rather than broadly suppressing the immune system. Its Deep Biology platform is capable of mapping the functional profiles of Tregs in human skin, gut, and lung tissues, thereby identifying targets and validating them using proprietary in vitro Treg models and high-throughput functional screening methods.